Sermorelin Dosage in the Clinical Research Literature
Sermorelin dosage as reported in the published clinical research falls into three distinct registers: pediatric treatment, pediatric provocative testing, and adult research. This section documents what was administered in published trials. It is not a recommendation and not a prescription; clinical decisions belong to clinicians and the regulatory environment surrounding compounded preparations is non-trivial.
The canonical pediatric treatment dose is 30 mcg/kg subcutaneously at bedtime, once daily, as administered to 110 prepubertal children with idiopathic GHD by the Thorner / international multi-site study group 03. The canonical pediatric diagnostic dose is 1 mcg/kg IV as a single provocative test bolus 06. Adult research has used either weight-based doses — Khorram's 10 mcg/kg subcutaneously nightly for 16 weeks in nineteen adults aged 55-71 09 — or fixed-microgram regimens reported in the range of 0.2-0.5 mg subcutaneously nightly in older-adult studies.
Dosing in the Clinical Research Literature
Pediatric GHD trials used 30 mcg/kg subcutaneously at bedtime 03. Adult research has explored fixed-microgram doses; framing here is studied-at, not prescriptive. Vittone's elderly-male cohort used single nightly GHRH (1-29) injections 10; Khorram's mixed-sex cohort used 10 mcg/kg subcutaneously nightly for 16 weeks 09.
Sermorelin Half-Life and Pharmacokinetics
Sermorelin half-life in human plasma is short — approximately 11-12 minutes after intravenous or subcutaneous administration, with clearance of approximately 2.4-2.8 L/min, per Frohman and colleagues 05. Tmax after subcutaneous dosing is roughly 5-20 minutes. Clearance is via rapid renal ultrafiltration and N-terminal proteolytic degradation.
The key pharmacokinetic-pharmacodynamic finding: the GH-secretory effect substantially outlasts the peptide's plasma presence. Ishida and colleagues documented that the GH pulse continues 2-4 hours after a single subcutaneous Sermorelin injection, despite plasma Sermorelin clearing within approximately one hour 12. The persistence reflects receptor-level signaling and downstream synthesis-release coupling, not continued circulating drug. PEGylation and D-Ala2 substitution have been the principal strategies for extending plasma half-life across the GHRH-analog class — the modified analogs of Esposito and colleagues and the trans-3-hexenoic acid stabilization that defines tesamorelin both addressed the rapid-clearance ceiling 1316.
Sermorelin Half-Life
Plasma half-life is short, on the order of 10-20 minutes, due to rapid proteolytic degradation; the GH-secretory effect persists longer than plasma levels would suggest 0512. The pharmacodynamic-pharmacokinetic mismatch is the central feature of Sermorelin pharmacology and the reason a 12-minute plasma half-life produces a 2-4-hour GH pulse.
Subcutaneous Injection in Clinical Studies
Sermorelin injection in published trials is overwhelmingly subcutaneous and overwhelmingly administered at bedtime. The mechanistic reason: endogenous GH release is largely nocturnal and pulsatile, and dosing at bedtime aligns the amplified GHRH signal with the body's intrinsic secretory rhythm.
A second mechanistic constraint: continuous (non-pulsatile) administration produces tachyphylaxis at the somatotroph — the cell rapidly downregulates its response — while intermittent bedtime dosing preserves responsiveness over the course of months of treatment 18. This is why pediatric GHD trials used nightly single subcutaneous injections rather than continuous infusion or twice-daily dosing.
Route of Administration
Subcutaneous injection, typically into the abdomen or thigh, administered at bedtime to align with the body's nocturnal GH pulse 0309. The provocative-testing literature uses the intravenous route for the 1 mcg/kg diagnostic bolus to obtain a rapid, time-defined GH response 06.
Editorial Pause: Why the Bedtime Pulsatile Regimen
The bedtime intermittent regimen is not an accident of convention. It is the mechanistic consequence of two facts: GHRH-receptor tachyphylaxis under continuous exposure 18, and the nocturnal-dominant phase of endogenous GH release. Continuous-infusion GHRH analogs blunt the somatotroph response within hours; intermittent dosing aligned with the nocturnal pulse window preserves both responsiveness and physiological rhythm.
This is also the mechanistic boundary that separates Sermorelin from longer-acting GHRH analogs. A longer half-life is not, in this class, an unambiguous improvement — it has to be matched against the tachyphylaxis constraint. Tesamorelin's longer half-life is paired with daily dosing in the HIV-lipodystrophy indication for the same physiological reason 1318.
The pediatric Thorner cohort's bedtime regimen was not improvised either — it derived from the prior 1980s clinical pharmacology of GHRH, in which Vance and colleagues established that intermittent dosing schedules better preserve the somatotroph response than continuous infusion 18. This is the rationale that survives across the entire GHRH-analog class: the timing of the signal matters as much as the amplitude.
Adult research has occasionally explored alternative schedules — twice-daily dosing, morning dosing — but the bedtime nightly schedule remains the published-trial default for the same mechanistic reason. The Khorram 16-week adult cohort used 10 mcg/kg subcutaneously nightly at bedtime for this reason 09; the Vittone elderly-male cohort used single nightly injections 10. A clinician designing a research protocol around Sermorelin without engaging the tachyphylaxis and nocturnal-pulse constraints is likely to repeat avoidable methodological errors that the 1980s GHRH-analog literature already worked through.